NRX Pharmaceuticals Files 8-K on Financials

Ticker: NRXPW · Form: 8-K · Filed: Mar 21, 2025 · CIK: 1719406

Nrx Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyNrx Pharmaceuticals, INC. (NRXPW)
Form Type8-K
Filed DateMar 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, regulation-fd, company-name-change

Related Tickers: NRXP

TL;DR

NRXP filed an 8-K on March 17th detailing financials and operations.

AI Summary

NRX Pharmaceuticals, Inc. filed an 8-K on March 21, 2025, reporting on results of operations, financial condition, and Regulation FD disclosures as of March 17, 2025. The filing includes financial statements and exhibits, with the company incorporated in Delaware and formerly known as Big Rock Partners Acquisition Corp. until October 12, 2017.

Why It Matters

This 8-K filing provides crucial updates on NRX Pharmaceuticals' financial performance and regulatory disclosures, which are important for investors to assess the company's current standing.

Risk Assessment

Risk Level: low — This filing is a standard 8-K reporting routine financial and operational information, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for NRX Pharmaceuticals, Inc.?

The primary purpose is to report on the company's Results of Operations and Financial Condition, Regulation FD Disclosure, and to file Financial Statements and Exhibits.

What was NRX Pharmaceuticals, Inc. formerly known as?

NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp.

When did the company change its name from Big Rock Partners Acquisition Corp.?

The company changed its name on October 12, 2017.

What is the state of incorporation for NRX Pharmaceuticals, Inc.?

The company is incorporated in Delaware.

What is the earliest event date reported in this 8-K filing?

The earliest event date reported is March 17, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 21, 2025 regarding NRX Pharmaceuticals, Inc. (NRXPW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing